Genitourinary Cancer
Conference Coverage
Hypogonadism after testicular cancer treatment can have lifelong impact
CHICAGO – Men with low testosterone in a cohort study of 491 testicular cancer survivors were more likely to be taking medications for...
Conference Coverage
ADT+RT duration can safely be shortened in high risk PC
CHICAGO – There may be a new standard of care on the horizon for patients with PC.
Conference Coverage
VIDEO: Survival improves when cancer patients self-report symptoms
CHICAGO – With improved survival and a host of other benefits, why wouldn’t you encourage your patients to self-report?
Conference Coverage
Immune-agonist combo has activity against several tumor types
CHICAGO – How can we improve responses in heavily pretreated patients with a variety of tumor types?
Conference Coverage
Test goes wide and deep to detect free tumor DNA in blood
CHICAGO – The high-intensity method for detecting circulating free DNA (cfDNA) in plasma found at least one significant genetic variant in samples...
Conference Coverage
VIDEO: Abiraterone improves survival in high-risk prostate cancer
CHICAGO – Adding abiraterone acetate plus prednisone to androgen deprivation therapy in hormone-naive prostate cancer patients significantly...
Conference Coverage
VIDEO: Low testosterone common after testicular cancer
CHICAGO – Survivors with hypogonadism are more likely than survivors with normal testosterone levels to have a range of chronic health problems....
News
FDA approves pembrolizumab for advanced urothelial carcinoma
Pembrolizumab is the third checkpoint inhibitor approved for bladder cancer this month.
From the Journals
Alternating therapy in renal cell carcinoma fails to show an advantage
Everolimus alternating with pazopanib and pazopanib alone were compared in a randomized, multicenter controlled trial.
Conference Coverage
More early-stage cancer diagnosis since ACA implementation
Though the increase is small, cancer has been detected earlier and more often, indicating future improvements in care.
News
FDA approves avelumab for advanced urothelial carcinoma
The drug is approved for second-line use following platinum-containing chemotherapy.